NASDAQ:MCRB

Seres Therapeutics (MCRB) Stock Forecast, Price & News

$2.39

0.00 (0.00%)

(As of 09/28/2023 ET)

Compare

Today's Range: $2.29
▼
$2.42
50-Day Range: $2.33
▼
$5.07
52-Week Range: $2.28
▼
$9.49

Volume: 2.69 million shs
Average Volume: 2.23 million shs
Market Capitalization: $306.42 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.67

Seres Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 471.8% Upside
$13.67 Price Target
Short Interest: Bearish
15.91% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.14
Upright™ Environmental Score
News Sentiment: 0.98
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.14) to ($1.58) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

490th out of 969 stocks

Pharmaceutical Preparations Industry

226th out of 455 stocks

3.4

Analyst's Opinion

Consensus Rating
Seres Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.67, Seres Therapeutics has a forecasted upside of 471.8% from its current price of $2.39.
Amount of Analyst Coverage
Seres Therapeutics has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
15.91% of the outstanding shares of Seres Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Seres Therapeutics has a short interest ratio ("days to cover") of 9.6.
Change versus previous month
Short interest in Seres Therapeutics has recently increased by 0.84%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Seres Therapeutics does not currently pay a dividend.
Dividend Growth
Seres Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Seres Therapeutics has received a 71.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Seres Therapeutics is -1.14.

3.9

News and Social Media Coverage

News Sentiment
Seres Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Seres Therapeutics this week, compared to 2 articles on an average week.
Search Interest
28 people have searched for MCRB on MarketBeat in the last 30 days. This is an increase of 65% compared to the previous 30 days.
MarketBeat Follows
11 people have added Seres Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Seres Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Seres Therapeutics is held by insiders.
Percentage Held by Institutions
87.93% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Seres Therapeutics are expected to decrease in the coming year, from ($1.14) to ($1.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Seres Therapeutics is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Seres Therapeutics is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Seres Therapeutics has a P/B Ratio of 26.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Seres Therapeutics (NASDAQ:MCRB) Stock

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MCRB Price History

30 days | 90 days | 365 days | Advanced Chart

MCRB Stock News Headlines

September 24, 2023 | americanbankingnews.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Recommendation of "Moderate Buy" from Analysts

September 11, 2023 | msn.com

Seres: VOWST Is A Great Product But Commercialization Prospects Unclear Due To Very High Price

September 28, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 7, 2023 | finance.yahoo.com

Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

September 1, 2023 | msn.com

Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy

August 9, 2023 | markets.businessinsider.com

Seres Therapeutics (MCRB) Receives a Sell from Goldman Sachs

August 9, 2023 | finance.yahoo.com

Investors Don't See Light At End Of Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Tunnel

August 8, 2023 | msn.com

Seres Therapeutics' Q2 Revenues Top Estimates; Reports Encouraging VOWST Early Commercial Uptake

September 28, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 8, 2023 | finance.yahoo.com

Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates

August 8, 2023 | benzinga.com

Earnings Outlook For Seres Therapeutics

August 8, 2023 | finance.yahoo.com

Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 3, 2023 | msn.com

Seres Therapeutics: VOWST's Time To Shine

August 1, 2023 | finance.yahoo.com

Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

August 1, 2023 | finance.yahoo.com

Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023

July 25, 2023 | markets.businessinsider.com

'Walk Away From It': Jim Cramer On This US Telecom Service Provider

July 10, 2023 | seekingalpha.com

Seres Therapeutics: Microbiome Therapeutics Amid High Operational Costs And Uncertain Profitability Path

July 7, 2023 | finance.yahoo.com

Seres Therapeutics (NASDAQ:MCRB) shareholders have endured a 47% loss from investing in the stock five years ago

June 21, 2023 | finance.yahoo.com

Seres Therapeutics Named to TIME100 Most Influential Companies List

June 17, 2023 | finance.yahoo.com

Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

June 5, 2023 | msn.com

Seres, Nestle Health announce US launch of c. diff therapy Vowst

June 5, 2023 | finance.yahoo.com

Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection

June 2, 2023 | finance.yahoo.com

Seres Therapeutics to Present at Jefferies Healthcare Conference

May 30, 2023 | finance.yahoo.com

Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™

May 23, 2023 | fool.com

Seres Therapeutics (NASDAQ: MCRB)

May 23, 2023 | seekingalpha.com

Seres Q1 Earnings: Major News For Investors

May 22, 2023 | seekingalpha.com

Seres Therapeutics: Still Work To Do Before Realizing Its Potential

See More Headlines

Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Company Calendar

Last Earnings: 8/08/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MCRB
CUSIP: N/A
CIK: 1609809
Web: www.serestherapeutics.com
Phone: (617) 945-9626
Fax: N/A
Employees: 431
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.67
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +484.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-250,160,000.00
Net Margins: -3,509.50%
Pretax Margin: -117.68%
Return on Equity: -1,155.47%
Return on Assets: -45.89%

Debt

Debt-to-Equity Ratio: 4.45
Current Ratio: 3.23
Quick Ratio: 3.16

Sales & Book Value

Annual Sales: $7.13 million
Price / Sales: 42.08
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.09 per share
Price / Book: 26.00

Miscellaneous

Outstanding Shares: 128,210,000
Free Float: 122,051,000
Market Cap: $300.01 million
Optionable: Optionable
Beta: 2.63

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Eric D. Shaff M.B.A. (Age 47)
Pres, CEO & Director
Comp: $1.07M

Mr. David A. Arkowitz M.B.A. (Age 62)
Exec. VP, CFO & Head of Bus. Devel.
Comp: $670.02k

Dr. Matthew R. Henn Ph.D. (Age 48)
Exec. VP & Chief Scientific Officer
Comp: $643.83k

Ms. Paula A. Cloghessy SHRM-SCP (Age 51)
SPHR, Exec. VP & Chief People Officer
Comp: $521.27k

Dr. Lisa von Moltke M.D. (Age 64)
Exec. VP & Chief Medical Officer
Comp: $706.14k

Dr. David S. Ege Ph.D. (Age 48)
Exec. VP & Chief Technology Officer

Mr. Carlo Tanzi Ph.D.
Investor Relations Officer

Mr. Thomas J. DesRosier Esq. (Age 68)
J.D., Chief Legal Officer, Exec. VP & Sec.

Dr. Teresa L. Young Ph.D. (Age 56)
R.Ph., Exec. VP and Chief Commercial & Strategy Officer

Ms. Caroline Holda
Assistant Gen. Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MCRB Stock - Frequently Asked Questions

Should I buy or sell Seres Therapeutics stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MCRB shares.
View MCRB analyst ratings or view top-rated stocks.
What is Seres Therapeutics' stock price forecast for 2023?: 5 analysts have issued 1 year price targets for Seres Therapeutics' shares. Their MCRB share price forecasts range from $7.00 to $25.00. On average, they predict the company's share price to reach $13.67 in the next twelve months. This suggests a possible upside of 484.0% from the stock's current price.
View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts.
How have MCRB shares performed in 2023?: Seres Therapeutics' stock was trading at $5.60 at the beginning of the year. Since then, MCRB stock has decreased by 58.2% and is now trading at $2.34.
View the best growth stocks for 2023 here.
When is Seres Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our MCRB earnings forecast.
How were Seres Therapeutics' earnings last quarter?: Seres Therapeutics, Inc. (NASDAQ:MCRB) released its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by $0.19. The biotechnology company earned $126.50 million during the quarter, compared to analysts' expectations of $125.67 million. Seres Therapeutics had a negative net margin of 3,509.50% and a negative trailing twelve-month return on equity of 1,155.47%. Seres Therapeutics's revenue for the quarter was up 10441.7% on a year-over-year basis. During the same period last year, the firm earned ($0.70) earnings per share.
What ETF holds Seres Therapeutics' stock ?: Simplify Propel Opportunities ETF holds 550,626 shares of MCRB stock, representing 2.57% of its portfolio.
What other stocks do shareholders of Seres Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?: (MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.
What is Seres Therapeutics' stock symbol?: Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."
Who are Seres Therapeutics' major shareholders?: Seres Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (6.68%), BlackRock Inc. (5.84%), Geode Capital Management LLC (1.53%), Jennison Associates LLC (1.09%), Point72 Asset Management L.P. (0.80%) and Handelsbanken Fonder AB (0.78%). Insiders that own company stock include David S Ege and Health Ltp Fund Ge Nutritional.
View institutional ownership trends.
How do I buy shares of Seres Therapeutics?: Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Seres Therapeutics' stock price today?: One share of MCRB stock can currently be purchased for approximately $2.34.
How much money does Seres Therapeutics make?: Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $300.01 million and generates $7.13 million in revenue each year. The biotechnology company earns $-250,160,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis.
How many employees does Seres Therapeutics have?: The company employs 431 workers across the globe.
How can I contact Seres Therapeutics?: Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com.

This page (NASDAQ:MCRB) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial